Determination of parathyroid hormone: from radioimmunoassay to LCMS/MS.
Cavalier EtiennePublished in: Clinical chemistry and laboratory medicine (2023)
Parathyroid hormone (PTH) determination is of paramount importance for the exploration of diseases related with calcium metabolism and for the follow-up of patients suffering from bone and mineral disorders associated with chronic kidney diseases (CKD-MBD). Unfortunately, the biologically active form of PTH, i.e. 1-84 PTH, circulates in the blood stream with many fragments and post-translationally modified forms, which decreases the specificity of immunoassays. The assays used to measure PTH, either from 2nd or 3rd generation, are not standardised, which may lead to interpretation errors and clinical consequences. Reference ranges for PTH have neither been always correctly established and the stability of the peptide is also a matter of concern. Fortunately, these last years, newer techniques using mass spectrometry (either high resolution or triple quadripole) coupled with liquid chromatography have been developed, which will help to standardise the different assays. Indeed, PTH assays standardisation is one of the task of the IFCC Committee for Bone Metabolism. Such standardisation will allow a better consistency in the interpretation of the results and will promote studies aiming at the establishment of correct reference ranges.
Keyphrases
- mass spectrometry
- liquid chromatography
- high resolution
- end stage renal disease
- high throughput
- chronic kidney disease
- solid phase extraction
- tandem mass spectrometry
- bone mineral density
- newly diagnosed
- ejection fraction
- high resolution mass spectrometry
- multiple sclerosis
- high performance liquid chromatography
- gas chromatography
- peritoneal dialysis
- ms ms
- patient reported outcomes
- bone loss
- prognostic factors
- body composition
- postmenopausal women
- emergency department
- structural basis